Eli Lilly

News

Lilly ups spend on diabetes, obesity drug production to $9bn

Eli Lilly is determined not to be left behind when it comes to manufacturing capacity for new diabetes and obesity therapies, raising its spending on a new plant in Indian

News

Regeneron gene therapy restores hearing in deaf child

Regeneron’s gene therapy for otoferlin-related hearing loss – a genetic cause of deafness – has restored hearing to normal levels in one profoundly deaf child within just

News

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

The FDA has confirmed that it will convene an advisory committee meeting on 10th June to discuss Eli Lilly’s Alzheimer’s disease candidate donanemab, after announcing a de

News

Wegovy sales double, as starting restrictions start to lift

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy

News

Trials set up filing for Lilly’s tirzepatide in sleep apnoea

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.

News

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me

Lilly ups spend on diabetes, obesity drug production to $9bn

Regeneron gene therapy restores hearing in deaf child

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

Wegovy sales double, as starting restrictions start to lift

Trials set up filing for Lilly’s tirzepatide in sleep apnoea

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

Eli Lilly

Editor's Picks